New antirheumatic substance based on phenolic glycoside structure methyl (4-O-B-glucopyranosyloxy)-benzoic acid

Nemtsev Alexey, Smirnov Ivan, Murashko Tatyana, Ivanov Alexey, Bondarev Alex, Udut Vladimir

Research output: Contribution to journalArticlepeer-review


Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID). Patients with rheumatoid arthritis are vulnerable to NSAID-associated gastrointestinal complications. Based on these findings we developed a new NSAID agent based on phenolic glycoside structure methyl (4-О-β-glucopyranosyloxy)-benzoic acid. In this study we evaluated the methyl (4-О-β-glucopyranosyloxy)-benzoic acid therapeutic effect in adjuvant-induced rat arthritis compared to etoricoxib effect. According to the results, methyl (4-О-β-glucopyranosyloxy)-benzoic acid activity was superior to etoricoxib, paw volume returned to the initial value 2 days early, than it did in etoricoxib group. Therefore, methyl (4-О-β-glucopyranosyloxy)-benzoic acid might contest to the modern antirheumatic drug etoricoxib.

Original languageEnglish
Pages (from-to)79-82
Number of pages4
JournalJurnal Teknologi
Issue number6-8
Publication statusPublished - 1 Jan 2016


  • Adjuvant arthritis
  • Phenolic glycosides
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Engineering(all)

Fingerprint Dive into the research topics of 'New antirheumatic substance based on phenolic glycoside structure methyl (4-O-B-glucopyranosyloxy)-benzoic acid'. Together they form a unique fingerprint.

Cite this